A marine microbiome antifungal targets urgent-threat drug-resistant fungi.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33214279.
- Also identified by DOI 10.1126/science.abd6919 and PMC identifier 7756952.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New antifungal drugs are urgently needed to address the emergence and transcontinental spread of fungal infectious diseases, such as pandrug-resistant <i>Candida auris.</i> Leveraging the microbiomes of marine animals and cutting-edge metabolomics and genomic tools, we identified encouraging lead antifungal molecules with in vivo efficacy. The most promising lead, turbinmicin, displays potent in vitro and mouse-model efficacy toward multiple-drug-resistant fungal pathogens, exhibits a wide safety index, and functions through a fungal-specific mode of action, targeting Sec14 of the vesicular trafficking pathway. The efficacy, safety, and mode of action distinct from other antifungal drugs make turbinmicin a highly promising antifungal drug lead to help address devastating global fungal pathogens such as <i>C. auris.</i>
Medical subject headings
- Antifungal Agents
- Benzopyrans
- Candida
- Candidiasis, Invasive
- Drug Resistance, Multiple, Fungal
- Isoquinolines
- Micromonospora
- Urochordata